Healthcare worker access to molnupiravir: A case series

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Molnupiravir is an oral antiviral effective in reducing COVID-19 severity.
• Australian Pharmaceutical Benefits Scheme (PBS) access to molnupiravir is restricted for those under 70 without specific risk factors, excluding most healthcare workers.
• Australian healthcare services face significant strain due to COVID-19-related staff shortages.

Purpose of the Study:

• To evaluate the effectiveness and safety of molnupiravir in Australian healthcare workers ineligible for PBS.
• To assess the impact of early molnupiravir treatment on illness duration, return to work, and household transmission.
• To explore the potential benefits of expanded molnupiravir access for healthcare workforce wellbeing and system capacity.

Main Methods:

• A study involving thirty tertiary hospital staff members who received molnupiravir within five days of COVID-19 diagnosis.
• Data collection on adverse events, duration of illness, return-to-work status, and household transmission.
• Analysis of outcomes in a cohort not meeting standard PBS eligibility criteria.

Main Results:

• All participants completed molnupiravir treatment with low rates of adverse events, comparable to clinical trial data.
• Median illness duration was four days, with 81% testing negative by rapid antigen test on the final treatment day.
• 73% were well enough to return to work post-isolation, and only 22% reported household transmission after starting treatment.

Conclusions:

• Early molnupiravir treatment offers individual health benefits for healthcare workers, including faster recovery and reduced transmission.
• Expanding access to molnupiravir for healthcare workers could mitigate staff shortages and enhance healthcare system resilience.
• Policy adjustments regarding molnupiravir access may support the wellbeing of essential healthcare personnel during the pandemic.